Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer

Shira Sherman, Zachary M. Sandusky, Douglas Russo, David Zak, Agostina Nardone, Delia Friel, Francisco Hermida-Prado, Capucine Heraud, Genevra Kuziel, Ana Verma, Giorgio Gaglia, Sheheryar Kabraji, Quang-De Nguyen, Sandro Santagata, Sean W. Fanning, Rinath Jeselsohn

Open source

DOI: 10.1172/jci.insight.188051
Published: 2025-05-06
Container: JCI Insight
Publisher: American Society for Clinical Investigation
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1172/jci.insight.188051,
  title = {Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer},
  author = {Shira Sherman and Zachary M. Sandusky and Douglas Russo and David Zak and Agostina Nardone and Delia Friel and Francisco Hermida-Prado and Capucine Heraud and Genevra Kuziel and Ana Verma and Giorgio Gaglia and Sheheryar Kabraji and Quang-De Nguyen and Sandro Santagata and Sean W. Fanning and Rinath Jeselsohn},
  year = {2025},
  journal = {JCI Insight},
  doi = {10.1172/jci.insight.188051},
  url = {https://doi.org/10.1172/jci.insight.188051}
}

RIS

TY  - JOUR
TI  - Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer
AU  - Shira Sherman
AU  - Zachary M. Sandusky
AU  - Douglas Russo
AU  - David Zak
AU  - Agostina Nardone
AU  - Delia Friel
AU  - Francisco Hermida-Prado
AU  - Capucine Heraud
AU  - Genevra Kuziel
AU  - Ana Verma
AU  - Giorgio Gaglia
AU  - Sheheryar Kabraji
AU  - Quang-De Nguyen
AU  - Sandro Santagata
AU  - Sean W. Fanning
AU  - Rinath Jeselsohn
PY  - 2025
JO  - JCI Insight
DO  - 10.1172/jci.insight.188051
UR  - https://doi.org/10.1172/jci.insight.188051
ER  -

APA

Sherman, S., Sandusky, Z. M., Russo, D., Zak, D., Nardone, A., Friel, D., Hermida-Prado, F., Heraud, C., Kuziel, G., Verma, A., Gaglia, G., Kabraji, S., Nguyen, Q., Santagata, S., Fanning, S. W., & Jeselsohn, R. (2025). Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer. JCI Insight. https://doi.org/10.1172/jci.insight.188051

Source records

crossref · retrieved 2026-09-25T09:38:33.750Z